Anti-VEGF therapy is the current gold standard of treatment for patients suffering from advanced wet AMD, which is characterized by an at least partially VEGF-induced growth of new blood vessels into the subretinal space, where bleeding, swelling, and later scarring lead to a rapid loss in central vision [37]. Here, VEGFA is linked to wet macular degeneration.